Corvidia

What Corvidia does

Corvidia Therapeutics is a privately held, clinical-stage biopharmaceutical company founded in 2014 and headquartered in Waltham, Massachusetts. The company focuses on the research and development of therapies targeting cardio-renal diseases — conditions at the intersection of cardiovascular and renal dysfunction — and operates with a small team of 11–50 employees. Its therapeutic approach is supported by a syndicate of specialized life-sciences investors, including Apple Tree Partners, Sofinnova Partners, Venrock, HBM Healthcare Investments, Cormorant Asset Management, Andera Partners, MedImmune, and Fresenius Medical Care, the latter two providing strategic exposure to biologics manufacturing and renal care delivery respectively.

The company's underlying technology centers on therapeutic candidates for cardio-renal indications, though specific molecules, mechanisms of action, and clinical trial stages are not detailed in the available data. The investor profile — particularly the participation of Fresenius Medical Care (a global dialysis leader) and MedImmune (AstraZeneca's biologics arm) — implies a development strategy aligned with biologics-based interventions and renal-care commercialization pathways. Corvidia has raised approximately $86.8 million across three disclosed funding rounds between 2016 and 2020.

Corvidia's business model is that of a pre-revenue R&D-driven biotech, monetizing not through commercial product sales but through eventual licensing, partnership, or M&A transactions with larger pharmaceutical or specialty care companies. Its near-term revenue mechanics rely on continued capital raises and strategic partnerships rather than product revenue. The company is led by Chairman Sylvie Gregoire; broader executive leadership and detailed operational data are not disclosed in the available source material.

Name

Corvidia

Website

https://corvidiatx.com

Company type

Private

Founded year

2014

Headcount range

11–50 employees

Short description

Corvidia Therapeutics is a privately held, clinical-stage biopharmaceutical company founded in 2014 in Waltham, Massachusetts, developing transformative therapies for cardio-renal diseases with a small R&D-focused team.

Ownership category

akta.pro rank

Product category

Cardio-Renal Therapeutics

akta.pro primary industry

Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation) (HLAHAFAL)

Keywords

• Cardio-renal therapeutics
• Biopharmaceutical research
• Novel therapeutic compounds
• Renal disease therapies
• Cardiovascular drug development

Headquarters

HQ city

Waltham

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Core offering

Corvidia Therapeutics is a clinical-stage biopharmaceutical company focused on the research and development of transformative therapies for cardio-renal diseases. The company develops novel therapeutic compounds targeting cardiovascular and renal conditions, an area of significant unmet medical need.

Differentiator

Problem solved

Functional benefit

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves5 records

Expansion highlights4 records

Direct peers

• Ardelyx, Inc. Ardelyx develops therapeutics for renal diseases, including CKD and dialysis-related indications — a directly comparable cardio-renal-adjacent biotech targeting kidney patients with high CV comorbidity.
• Akebia Therapeutics: Akebia Therapeutics focuses on anemia of CKD (vadadustat) — a cardio-renal therapeutic area sharing the same patient population (CKD patients with elevated CV risk) and overlapping clinical trial design.
• Relypsa (a Vifor Pharma company): Relypsa developed patiromer for hyperkalemia in CKD and CV patients — a textbook cardio-renal therapeutic; acquired by Galenica/Vifor. Closely comparable therapeutic, patient population, and indication strategy to a cardio-renal biotech.
• Tricida, Inc. Tricida developed veverimer for metabolic acidosis in CKD, with explicit CV outcomes rationale — a directly comparable small-molecule cardio-renal story at similar development stage and patient population.
• Keryx Biopharmaceuticals: Keryx developed ferric citrate for hyperphosphatemia in CKD/dialysis patients (later acquired by Akebia) — a direct comparable cardio-renal biotech with a similar focused-kidney-disease profile and small-cap exit path.

Emerging players

• Lexicon Pharmaceuticals: Lexicon develops sotagliflozin for heart failure and CKD — overlapping cardio-renal indication footprint and similar small-public-company development-stage profile to Corvidia.
• ProKidney Inc. ProKidney develops cell-therapy approaches for CKD, targeting the same cardio-renal patient population with a novel modality — comparable strategic interest of CV-pharma buyers for kidney disease assets.
• Cara Therapeutics: Cara Therapeutics developed difelikefalin for chronic kidney disease–associated pruritus in dialysis patients and explored CV/renal indications — directly overlapping cardio-renal therapeutic focus and small-cap biotech profile.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/corvidia-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds3 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Corvidia